Minretumomab  (Synonyms: CC-49)

Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research^[1][2].

Mouse IgG1 kappa

Mouse IgG1 kappa, Isotype Control

Human

The combination therapy of minretumomab and gemcitabine shows antitumor effects in murine colon cancer models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.06 kDa

195189-17-4

Liquid

Colorless to light yellow

[Minretumomab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa

• 
  Flow cytometric analysis of 1.5×10⁶ NCI-H1703 cells with Minretumomab (HY-P99732, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Mouse IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG1 kappa Isotype Control (HY-P99977, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Graves SS, et al. Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3712-21.  [Content Brief]

  [2]. Sheikh N. Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute. Curr Opin Mol Ther. 2003 Aug;5(4):428-32.  [Content Brief]